Fig. 3.

MSDNc with a good proteolytic resistance, biological stability, GSH-responsive cargo release. (A&B) Residual peptide of L ^CtrlMSDc (A) and MSDc (B) in PBS treated by 0.5 mg/ml chymotrypsin for 12 h measured by HPLC. (C) Proteolysis resistance of MSDc (red) and ^CtrlMSDc (black) under PBS containing 0.5 mg/ml chymotrypsin. (D) TEM images of untreated MSDNc (left) and MSDNc treated with 10 mM GSH for 6 h (right). (E) Cargo release rate of MSDNc over time without no treatment (black) or after treated with 10 mM GSH (red) measured by HPLC. (F) Circular dichroism spectrum of MSDc (red line) and MSDNc (black line). (G) After treating cells with a drug concentration of 1 μM for 6 h, the uptake efficiency of FITC-labeled MSDNc and FITC-labeled MSDc by macrophages analysed by flow cytometry. (H) The fluorescence in bood of Cy3-labeled MSDc (black) and MSDNc (red) after tail vein injection at a dose of 1.5 mg/kg. (I-L) The content of EPO (I), IL2 (J), INF (K), and EOS (L) in the blood measured by ELASA after the above-mentioned administration.